Thus, in addition to inflicting replication‐associated DNA damage and suppressing PARP1/2‐dependent DNA repair, PARPis act by enhancing the immunogenicity of BRCA1/2‐deficient tumours, thereby facilitating their elimination by the immune system. Here, BRCA1 is linked to neoplasm.